Sigurd D. Süßmuth

Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials

Background: BI 1569912 is an orally administered, GluN2B-selective negative allosteric modulator at the N-methyl-D-aspartate receptor. Aims: To investigate the safety, tolerability and pharmacokinetics (PK) of BI 1569912 in healthy males across three partially randomised, placebo...

Dopaminergic modulation of social reward anticipation in depression: neural effects of amisulpride versus placebo

Abstract Reward processing deficits are a well-established mechanism underlying anhedonia, a core symptom of Major Depressive Disorder (MDD). Given the role of dopamine in mesocorticolimbic reward pathways, this study examined whether a single low dose of amisulpride (100 mg), wh...